Key result
GAT107 increases survival by ~200% vs vehicle in a mouse model of ventilator-associated pneumonia.
Why the study?
Hyperoxia compromises host defense and increases susceptibility to ventilator-associated pneumonia, mediated partly by high extracellular HMGB1 levels.
Does GAT107 reduce mortality and inflammatory lung injury in a mouse model of ventilator-associated pneumonia?
Does GAT107 reduce mortality and inflammatory lung injury in a mouse model of ventilator-associated pneumonia?
Absolute Event Rate: 60% vs 20%
p-value: p=<0.05
GAT107 attenuates inflammatory lung injury and mortality in a mouse model of ventilator-associated pneumonia by restoring macrophage phagocytic function via a mitochondrial-directed pathway.
This is the authors' abstract. We don't add key points for this paper.
Supraphysiological concentrations of oxygen (hyperoxia) can compromise host defense and increase susceptibility to bacterial and viral infections, causing ventilator-associated pneumonia (VAP). Compromised host defense and inflammatory lung injury are mediated, in part, by high extracellular concentrations of HMGB1, which can be decreased by GTS-21, a partial agonist of α7 nicotinic acetylcholine receptor (α7nAChR). Here, we report that a novel α7nAChR agonistic positive allosteric modulator (ago-PAM), GAT107, at 3.3 mg/kg, i.p., significantly decreased animal mortality and markers of inflammatory injury in mice exposed to hyperoxia and subsequently infected with Pseudomonas aeruginosa. The incubation of macrophages with 3.3 μM of GAT107 significantly decreased hyperoxia-induced extracellular HMGB1 accumulation and HMGB1-induced macrophage phagocytic dysfunction. Hyperoxia-compromised macrophage function was correlated with impaired mitochondrial membrane integrity, increased superoxide levels, and decreased manganese superoxide dismutase (MnSOD) activity. This compromised MnSOD activity is due to a significant increase in its level of glutathionylation. The incubation of hyperoxic macrophages with 3.3 μM of GAT107 significantly decreases the levels of glutathionylated MnSOD, and restores MnSOD activity and mitochondrial membrane integrity. Thus, GAT107 restored hyperoxia-compromised phagocytic functions by decreasing HMGB1 release, most likely via a mitochondrial-directed pathway. Overall, our results suggest that GAT107 may be a potential treatment to decrease acute inflammatory lung injury by increasing host defense in patients with VAP.
Hypothesis-generating for GAT107 in ventilator-associated pneumonia; requires clinical validation before therapeutic consideration.
No takes yet. Share an insight, caveat, or question.
Gauthier et al. (2023) studied Ventilator-associated pneumonia (VAP). GAT107 vs. Vehicle (DMSO) was evaluated on Survival rate at 24 hours post-infection (p=<0.05). GAT107 significantly increased the survival rate to 60% compared to 20% with vehicle control in a mouse model of ventilator-associated pneumonia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: